U.S. Based Medicinova Aims To Boost Efficiency In Japanese Drug Development
This article was originally published in PharmAsia News
California-based pharmaceutical venture company Medicinova plans to buy preclinical drug candidates in Japan that have been cleared for the clinic, and conduct more efficient clinical trials in Europe and the U.S., Medicinova President Yuichi Iwaki said in an interview in Mainichi News. Medicinova will then sell the products after the trials. Currently, Medicinova is developing 10 drugs, including Kissei's bronchitis and acute asthma candidate MN-221 and Kyorin's multiple sclerosis treatment MN-166. (Click for more-Japanese language
You may also be interested in...
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.